We also highlight the tryptophan catabolizing enzyme, IDO1, as a critical modulator of Treg recruitment and/or expansion to/within the glioma, as well as raise the possibility that enzymes with similar catabolic activity, IDO2 and TDO, may be attractive future targets for immunotherapeutic consideration. Here, TDO2 is linked to central nervous system cancer.